The survival of HER2 positive screen detected breast cancers in the abscence of chemotherapy and herceptin.

被引：0
|
作者：
Johnson, R. L. [1 ]
Prasad, R. [1 ]
Knox, W. F. [1 ]
Byrne, G. [1 ]
Morris, J. [1 ]
Cramer, A. [1 ]
Wilson, A. [1 ]
Bundred, N. J. [1 ]
机构：
[1] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S110 / S111
页数：2
相关论文
共 50 条
  • [41] Hormonal prevention of HER2 positive mammary cancers
    Subramani, Ramadevi
    Lakshmanaswamy, Rajkumar
    CANCER RESEARCH, 2018, 78 (04)
  • [42] Adjuvant chemotherapy for elderly HER2/neu positive breast cancer patients
    Miryusupova, G.
    Shayusupov, N.
    BREAST, 2015, 24 : S63 - S63
  • [43] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
  • [44] JAM-A is over-expressed in aggressive Her2 positive breast cancers
    Brennan, K.
    Roche, T.
    McSherry, E. A.
    O'Grady, T.
    Kay, E. W.
    Hopkins, A. M.
    EJC SUPPLEMENTS, 2010, 8 (05): : 93 - 93
  • [45] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
  • [46] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
  • [47] Borderline HER2 Protein Positive Breast Cancers Have Similar Patient Outcome Regardless of HER2 Gene Amplification Status
    Barros, F.
    Aleskandarany, M.
    Rakha, E.
    Watts, S.
    Powe, D.
    Ellis, I
    Green, A.
    JOURNAL OF PATHOLOGY, 2010, 222 : S23 - S23
  • [48] Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
    Angeles Lopez-Garcia, M.
    Carretero-Barrio, Irene
    Perez-Mies, Belen
    Chiva, Miguel
    Castilla, Carolina
    Vieites, Begona
    Palacios, Jose
    CANCERS, 2020, 12 (06) : 1 - 16
  • [49] CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells
    Xiang, Ru
    Han, Xiaowen
    Ding, Keshuo
    Wu, Zhengsheng
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (02)
  • [50] Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?
    de Munck, Linda
    Siesling, Sabine
    Bart, Joost
    Menke-Pluijmers, Marian B. E.
    Otter, Renee
    Willemse, Pax H. B.
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2013, 22 (05) : 398 - 403
12345